- Home
- / InMed Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
InMed Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.3
2024-10-29
Market Capitalization
$3.9 M
2024-10-29
Revenue
$4.9 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|
| Revenue | 1.1M | 4.1M | 4.6M | 4.9M | |
| Cost of goods sold | 545.9K | 2.4M | 3.5M | 3.2M | |
| Gross profit | 543.5K | 1.4M | 1.1M | 1.7M | |
| Gross profit margin, % | 49.9% | 33.9% | 23.9% | 34.5% | |
| General and administrative expense | 4.5M | 6.9M | 5.8M | 5.3M | |
| Operating expense total | 9.8M | 19.1M | 9.4M | 9.0M | |
| EBIT | (18.6M) | (7.9M) | |||
| EBIT margin, % | -1707.3% | -192.2% | |||
| Interest income | 16.0K | 96.1K | 492.4K | 527.9K | |
| Pre tax profit | (7.9M) | (7.7M) | (8.2M) | ||
| Income tax expense | 13.1K | 7.1K | |||
| Net Income | 10.2M | 18.6M | 7.9M | (7.7M) | |
| EPS | (33.2) | (3.2) | (1.0) | (8.4) |